Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.

Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M, REEF-1 Study Group.

Open source

DOI: 10.1016/s2468-1253(23)00148-6
Published: 2023-07-10
Container: Lancet Gastroenterol Hepatol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-23-00148-6,
  title = {Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.},
  author = {Yuen MF and  Asselah T and  Jacobson IM and  Brunetto MR and  Janssen HLA and  Takehara T and  Hou JL and  Kakuda TN and  Lambrecht T and  Beumont M and  Kalmeijer R and  Guinard-Azadian C and  Mayer C and  Jezorwski J and  Verbinnen T and  Lenz O and  Shukla U and  Biermer M and  REEF-1 Study Group.},
  year = {2023},
  journal = {Lancet Gastroenterol Hepatol},
  doi = {10.1016/s2468-1253(23)00148-6},
  url = {https://doi.org/10.1016/s2468-1253(23)00148-6}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
AU  - Yuen MF
AU  -  Asselah T
AU  -  Jacobson IM
AU  -  Brunetto MR
AU  -  Janssen HLA
AU  -  Takehara T
AU  -  Hou JL
AU  -  Kakuda TN
AU  -  Lambrecht T
AU  -  Beumont M
AU  -  Kalmeijer R
AU  -  Guinard-Azadian C
AU  -  Mayer C
AU  -  Jezorwski J
AU  -  Verbinnen T
AU  -  Lenz O
AU  -  Shukla U
AU  -  Biermer M
AU  -  REEF-1 Study Group.
PY  - 2023
JO  - Lancet Gastroenterol Hepatol
DO  - 10.1016/s2468-1253(23)00148-6
UR  - https://doi.org/10.1016/s2468-1253(23)00148-6
ER  -

APA

MF, Y., T, A., IM, J., MR, B., HLA, J., T, T., JL, H., TN, K., T, L., M, B., R, K., C, G., C, M., J, J., T, V., O, L., U, S., M, B., & Group., R. S. (2023). Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.. Lancet Gastroenterol Hepatol. https://doi.org/10.1016/s2468-1253(23)00148-6

Source records

europe-pmc · retrieved 2026-09-26T15:57:28.473Z